格雷夫斯病患者每六个月给予低剂量放射性碘治疗。
Low-dose radioiodine given six-monthly in Graves' disease.
作者信息
Hoskin P J, Spathis G S, McCready V R, Cosgrove D O, Harmer C L
出版信息
J R Soc Med. 1985 Nov;78(11):893-8. doi: 10.1177/014107688507801103.
Experience using low-dose radioiodine given six-monthly instead of yearly in hyperthyroid patients with Graves' disease is reported. One hundred and thirty-five patients have been treated over a three-year period with 74 MBq (2 mCi) doses of 131I. Thirty-eight percent were controlled with a single dose. Those patients requiring more than one dose were treated with a further 74 MBq (2 mCi) 131I at six-monthly intervals until euthyroid. Using this approach, 46% were euthyroid one year after starting treatment, and 75% were euthyroid at two years. The incidence of hypothyroidism following treatment was 2.2% at one year, with a yearly incidence thereafter of 4-6%. Six-monthly scheduling of low-dose radioiodine in Graves' disease can reduce the time taken to become euthyroid, compared with conventional yearly low-dose treatments. Further follow up is required to confirm the present low incidence of hypothyroidism following treatment.
报告了在患有格雷夫斯病的甲状腺功能亢进患者中每半年而非每年给予低剂量放射性碘的使用经验。在三年期间，135名患者接受了74MBq（2mCi）剂量的131I治疗。38%的患者单次剂量即可得到控制。那些需要多剂治疗的患者每隔六个月接受额外74MBq（2mCi）的131I治疗，直至甲状腺功能正常。采用这种方法，开始治疗一年后46%的患者甲状腺功能正常，两年时75%的患者甲状腺功能正常。治疗后一年甲状腺功能减退的发生率为2.2%，此后每年发生率为4 - 6%。与传统的每年低剂量治疗相比，格雷夫斯病每半年安排一次低剂量放射性碘治疗可缩短达到甲状腺功能正常所需的时间。需要进一步随访以确认目前治疗后甲状腺功能减退的低发生率。
Zotero 插件